Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
There was evidence for no association between the prevalence of e-cigarette use and ever regular smoking among those aged 16–24 [B = –0.015, 95% confidence interval (CI) = –0.046 to 0.016; P = 0.341; Bayes factor (BF) = 0.002]. Evidence for no association was also found in the stratified analysis among those aged 16–17 (B = 0.070, 95% CI –0.014 to 0.155, P = 0.102; BF = 0.015) and 18–24 (B = –0.021, 95% CI –0.053 to 0.011; P = 0.205; BF = 0.003)
The Royal Australian and New Zealand College of Psychiatrists (RANZCP) supports the legalisation and regulation of nicotine-containing e-cigarettes and other vaporised nicotine products to facilitate their use as harm reduction tools.
In this survey study of physicians, findings suggest that physicians may recommend switching to e-cigarettes for some patients who smoke cigarettes under certain circumstances, presumably for cessation.
In this US nationally representative cohort study of 1600 adult daily cigarette smokers who did not initially use e-cigarettes and had no plans to ever quit smoking, subsequent daily e-cigarette use was significantly associated with an 8-fold greater odds of cigarette discontinuation compared with no e-cigarette use.
There is moderate-certainty evidence that ECs with nicotine increase quit rates compared to NRT and compared to ECs without nicotine. Evidence comparing nicotine EC with usual care/no treatment also suggests benefit, but is less certain.
Compared to our 2018 report, there is stronger evidence in this year’s report that nicotine vaping products are effective for smoking cessation and reduction.
The trial results suggest that when treating smokers who failed with stop-smoking medications previously, recommending a refillable EC with an e-liquid of strength and flavours of the patient’s choice is a more effective approach than prescribing combination NRT.
Findings from a recent report commissioned by Public Health England, (PHE) demonstrated that e-cigarettes are the most popular aid used in quit attempts.
Combining well-established evidence from NRT trials and emerging evidence from e-cigarette trials, we found that nicotine e-cigarettes are effective in helping smokers quit smoking.
E-cigarettes were more effective for smoking cessation than nicotine-replacement therapy, when both products were accompanied by behavioral support.
Vitamin E acetate was associated with EVALI in a convenience sample of 51 patients in 16 states across the United States. (Funded by the National Cancer Institute and others.)
These findings support the premise that peers are a primary social influencer and reinforcer for vaping.
The information on this website is intended for medical practitioners and pharmacists interested in learning more about nicotine vaping products and how they can use them to assist their patients and customers with smoking cessation. It is not intended to promote the use of nicotine vaping products. From the Fields Pharmaceuticals Pty Ltd acknowledges the potential side-effects of nicotine vaping products as well as possible alternative treatments, and further information about these can be found on the TGA website.
From the Fields Pharmaceuticals Pty Ltd
Level 15, 45 Pirie Street, Adelaide SA 5000, Australia
Copyright © 2023 FTF Pharmaceutical - All Rights Reserved.
ACN 662 953 826
We use cookies to analyse website traffic and optimise your website experience. By clicking continue, your data will be aggregated with all other user data.